<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thalidomide alone (200-300 mg daily) or associated with <z:chebi fb="0" ids="23359">colchicine</z:chebi> (2-3 mg daily) was given orally to 25 patients with <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e>: 8 patients with <z:e sem="disease" ids="C0554021" disease_type="Disease or Syndrome" abbrv="">recurrent oral aphthae</z:e>; 4 patients with recurrent mucocutaneous <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e>, without visceral involvement, and 13 patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease (Touraine's <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>A major improvement was noted in <z:hpo ids='HP_0000001'>all</z:hpo> groups, with a rapid healing of mucous lesions and a rapid reduction of pain and burning as compared to prior spontaneous regressions </plain></SENT>
<SENT sid="2" pm="."><plain>No new outbreaks were noted at a dose of 50-100 mg thalidomide and 1 mg <z:chebi fb="0" ids="23359">colchicine</z:chebi> daily </plain></SENT>
<SENT sid="3" pm="."><plain>Under oral administration of the drugs, <z:hpo ids='HP_0004418'>thrombophlebitis</z:hpo> was noted in 1 case (third group) only </plain></SENT>
<SENT sid="4" pm="."><plain>In the other patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">disease, skin</z:e> <z:e sem="disease" ids="C0038363" disease_type="Disease or Syndrome" abbrv="">aphthae</z:e>, ocular symptoms, <z:hpo ids='HP_0001369'>arthritis</z:hpo>, superficial nodular <z:mp ids='MP_0010140'>phlebitis</z:mp> quickly disappeared with treatment </plain></SENT>
<SENT sid="5" pm="."><plain>The efficiency of the drugs is only temporary, since new lesions usually appeared a few weeks after the end of treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Due to the relatively small number of cases studied in each group, no conclusions can be drawn concerning the efficiency of thalidomide alone compared to the association of the two drugs </plain></SENT>
<SENT sid="7" pm="."><plain>However, this open trial does support the usefulness of thalidomide, or thalidomide and <z:chebi fb="0" ids="23359">colchicine</z:chebi>, in recurrent mucocutaneous <z:e sem="disease" ids="C0038363" disease_type="Disease or Syndrome" abbrv="">aphthae</z:e>, <z:e sem="disease" ids="C0016514" disease_type="Disease or Syndrome" abbrv="">aphthosis</z:e> and <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
</text></document>